Gene therapy

30 June 2020 Image: National Cancer Institute The San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) and Genespire have published data highlighting progress in the development of an improved targeted gene replacement technology in human hematopoietic stem cells (HSCs) in Nature Biotechnology. The paper, entitled Efficient gene editing of human long-term hematopoietic stem cells validated by […]

29 June 2020 Image: National Cancer Institute A type of drug already used to treat breast and ovarian cancer, called a PARP inhibitor, may be useful in treating children with high-risk neuroblastoma, a childhood tumour with a low survival rate, a new study suggests. Neuroblastoma is a cancer which arises from nerve cells in either […]

25 June 2020 Teknova has appointed Stephen Gunstream as chief executive officer. Gunstream has nearly 20 years of experience in the life sciences industry, including positions as Vice President and General Manager for the research and clinical business at BD Biosciences and Chief Commercial Officer at Integrated DNA Technologies. He joins Teknova as the company looks to […]

Avacta Group has announced that the first Affimer-based rapid test strips to detect SARS-COV-2 spike protein have been developed and evaluated by partners at Cytiva (formerly GE Healthcare Life Sciences) and show positive initial performance data. In mid-May Avacta provided Affimer reagents that are specific to the SARS-COV-2 spike protein to Cytiva which has now […]

Taconic Biosciences has announced an exclusive agreement with the University of Texas Medical Branch at Galveston (UTMB) to distribute humanised ACE2 mice for coronavirus research. The SARS-CoV-2 virus, which causes COVID-19, uses the ACE2 receptor to enter cells, causing infection. Due to differences between the mouse and human ACE2 receptors, normal laboratory mice cannot be […]

19 June 2020 AFFiRiS has announced that detailed results of the phase 1 clinical program with its lead candidate PD01 in early PD patients were published in the peer-reviewed journal The Lancet Neurology. Results of the phase 1 clinical program with AFFiRiS’ lead candidate PD01 in early Parkinson’s disease (PD) patients have been published in […]

Avacta Group, in collaboration with the Centre for Virus Research at the University of Glasgow, has shown that Affimer reagents which bind to the SARS-COV-2 virus spike protein, prevent infection of human cells by a SARS-COV-2 model virus and therefore provide a potential therapy for COVID-19 infection. Avacta Group, in collaboration with the Centre for […]

Cobra Biologics will provide GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222, previously known as ChAdOx1 n-CoV-19. Cobra Biologics, part of the Cognate BioServices family, an international CDMO for biologics and pharmaceuticals, has signed a supply agreement with AstraZeneca UK to provide GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222, previously known as […]

16 June, 2020 The global science-led biopharmaceutical company said the detailed results from both the Phase II ACE-CL-001 trial and the pivotal Phase III ASCEND trial showed the long-term efficacy and tolerability of Calquence (acalabrutinib) in chronic lymphocytic leukaemia (CLL), one of the most common types of adult leukaemia. AstraZeneca presented the results of the […]

15 June, 2020 Kite, which is part of research-based biopharmaceutical company Gilead Sciences, announced it has received approval to implement a variation to the Yescarta (axicabtagene ciloleucel) Marketing Authorisation from the European Medicines Agency (EMA) for end-to-end manufacturing at its facility located in Amsterdam, The Netherlands. With this approval, Kite said that its European manufacturing […]